At this year’s AAIC, the developer of an Alzheimer’s blood test debuts promising data, while the Alzheimer’s Association warns new blood-based biomarkers aren’t quite…
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
A new book by Dr. Jason Karlawish shares largely untold stories the history of the Alzheimer’s crisis, discussing the science, missed opportunities, and reasons…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
